ADNCD
   
 
 
Select Mode of Action
Anti-diabetic mode of action: Improving diabetes related disorders
Natural compounds reducing Diabetic Nephropathy/Diabetic Neuropathy/Diabetic Cataract/Cardio-vascular Complications
S.No. Compound Reference Reduced risk Physicochemical Properties and Toxicity Risks
1 Malvidin 3-glucosideYasujiro et al., 2002 Diabetic Cataract Properties and Risk Assessment
2 Delphinidin 3-glucosideYasujiro et al., 2002 Diabetic Cataract Properties and Risk Assessment
3 Petunidin 3-glucosideYasujiro et al., 2002 Diabetic Cataract Properties and Risk Assessment
4 Peonidin 3-glucosideYasujiro et al., 2002 Diabetic Cataract Properties and Risk Assessment
5 LuteinArnal et al., 2009 Sasaki et al., 2010 Diabetic Cataract Properties and Risk Assessment
6 NeferineLi et al., 2013 Guan et al., 2014Cardio-vascular complications Properties and Risk Assessment
7 Gallic acidPatel and Goyal, 2011Cardio-vascular complications Properties and Risk Assessment
8 Ginsenoside Rg1Hai-tao et al., 2015Cardio-vascular complications Properties and Risk Assessment
9 SulforaphaneBai et al., 2013Cardio-vascular complications Properties and Risk Assessment
10 KolavironAyepola et al., 2014Diabetic Nephropathy Properties and Risk Assessment
11 Rosmarinic acidJiang et al., 2012Diabetic Nephropathy Properties and Risk Assessment
12 ThymoquinoneOmran, 2014Diabetic Nephropathy Properties and Risk Assessment
13 BreviscapineZheng et al., 2015Diabetic Nephropathy Properties and Risk Assessment
14 Ursolic acidChen Ling et al., 2013Diabetic Nephropathy Properties and Risk Assessment
15 MangiferinLi et al., 2010Diabetic Nephropathy Properties and Risk Assessment
16 Oleanoic acidDubey et al., 2013Diabetic Nephropathy Properties and Risk Assessment
17 MyricetinOzcan et al., 2012Diabetic Nephropathy Properties and Risk Assessment
18 QuercetinAnjaneyulu and Chopra, 2004Diabetic Nephropathy Properties and Risk Assessment
19 Ginsenoside Rg1Ma et al., 2010Diabetic Nephropathy Properties and Risk Assessment
20 AstaxanthinNaito et al., 2004Diabetic Nephropathy Properties and Risk Assessment
21 TheobrominePapadimitriou et al., 2015Diabetic Nephropathy Properties and Risk Assessment
22 LycopeneKuhad et al., 2008Diabetic Neuropathy Properties and Risk Assessment
23 SalidrosideZhao et al., 2011Diabetic Neuropathy Properties and Risk Assessment
24 ResperineNadel, 1958Diabetic Neuropathy Properties and Risk Assessment
25 Rosmarinic acidLuan et al., 2013Diabetic Neuropathy Properties and Risk Assessment
26 BreviscapineZheng et al., 2015Diabetic Neuropathy Properties and Risk Assessment
27 Epigallocatechin GallateRaposo et al., 2015Diabetic Neuropathy Properties and Risk Assessment
28 NeferineLi et al., 2013Diabetic Neuropathy Properties and Risk Assessment
29 alpha-tocopherolRoldi et al., 2009Diabetic Neuropathy Properties and Risk Assessment
30 Gallic acidRaafat and Samy, 2014Diabetic Neuropathy Properties and Risk Assessment
31 HydroxytyrosolRistagno et al., 2012Diabetic Neuropathy Properties and Risk Assessment
32 GeraniolPrasad and Muralidhara 2014Diabetic Neuropathy Properties and Risk Assessment
33 TrigonellineZhou et al., 2012Diabetic Neuropathy Properties and Risk Assessment
34 ConophyllineKawakami et al., 2010Diabetic Neuropathy Properties and Risk Assessment
35 ReserpineBonini, 2003Diabetic Neuropathy Properties and Risk Assessment